Fatty liver disease (MASLD/MASH) trials in Canada

In Canada 18 Also abroad 367

18 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Edmonton, Hamilton, Montreal, Terrebonne, Toronto, Vaughan
Age
18 years to 80 years
People
1,650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Bridgewater, Calgary, Montreal, Québec, Terrebonne, Toronto, Vancouver
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Bridgewater, Calgary, Montreal, Québec, Toronto, Vancouver
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Calgary, London, Ottawa, Toronto, Vancouver, Vaughan, Winnipeg
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Calgary, London, Ottawa, Toronto, Vancouver, Vaughan, Winnipeg
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
Phase 2Taking people
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
Where
Edmonton
Age
18 years to 75 years
People
30 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07325526
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Edmonton, Montreal, Terrebonne, Toronto, Vaughan
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Calgary, Chicoutimi, Edmonton, Halifax, London, North Bay, Québec, Toronto, Trois-Rivières, Vancouver, Winnipeg
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
No phaseTaking people
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Where
Montreal
Age
18 years and over
People
102
Run by
Centre hospitalier de l'Université de Montréal (CHUM)
See details and how to joinNCT03572465
Phase 2Taking people
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Where
Toronto
Age
18 years to 75 years
People
120 worldwide
Run by
Madrigal Pharmaceuticals, Inc.
See details and how to joinNCT07335601
Phase 4Taking people
Fibrosis Lessens After Metabolic Surgery
Where
Montreal
Age
18 years to 75 years
People
120 worldwide
Run by
The Cleveland Clinic
See details and how to joinNCT06374875
Phase 3Taking people
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Where
Québec
Age
18 years to 75 years
People
1,200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221227
No phaseTaking people
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Where
Sherbrooke
Age
20 years to 80 years
People
36
Run by
Université de Sherbrooke
See details and how to joinNCT06843148
No phaseTaking people
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
Where
London
Age
18 years and over
People
124
Run by
Anton Skaro
See details and how to joinNCT05884723
Phase 1Taking people
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Where
Toronto
Age
18 years to 64 years
People
52
Run by
1Globe Health Institute
See details and how to joinNCT06694935
No phaseNot yet taking people in Canada
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Where
Québec
Age
18 years and over
People
120
Run by
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
See details and how to joinNCT06764056
No phaseTaking people
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
Where
Québec
Age
18 years to 75 years
People
70
Run by
Valbiotis
See details and how to joinNCT06704321
Phase 2Taking people
Soluble Fibre Supplementation in NAFLD
Where
Hamilton
Age
8 years to 17 years
People
60
Run by
McMaster University
See details and how to joinNCT05480696